iBET at NextGen Biomed 2025: Patricia Alves Presents MS-based Bioanalytics for Efficient DSP Polishing Platform Characterization
Leveraging MS-based Tools for Efficient DSP Polishing Platform Characterization
iBET scientists recently participated in the NextGen Biomed Conference, held in London, UK, from March 12-14.
Patricia Gomes-Alves, Head of the Sanofi Satellite Lab at iBET, delivered an oral presentation on “Leveraging MS-based Tools for Efficient DSP Polishing Platform Characterization” as part of Track 3 – Downstream Development Protein Purification & Recombinant Protein Production.
Her talk focused on the use of mass spectrometry (MS)-based bioanalytical tools to optimize monoclonal antibody (mAb) purification, highlighting:
- A Multiple Attribute Method (MAM) strategy to assess post-translational modifications (PTMs) in mAbs (S Carvalho et al., PloS One, 2022).
- A SWATH-MS approach for quantifying high-risk host cell proteins (HCPs) (S Carvalho et al., J Biotechnol, 2024).
These advanced bioanalytical tools were developed to characterize a downstream polishing platform, enabling the identification of the optimal design space to maximize product quality and purification performance. This work resulted from two collaborative studies between iBET and Sanofi researchers.
Left: Patricia Gomes-Alves delivering her presentation. Right: Patricia participating in the roundtable discussion alongside fellow scientists and leaders: Amita Vaidya, Mihaela Bozic and Alexandria Cogdill.
Beyond her scientific presentation, Patricia also participated in the “Women in NextGen Biomed” roundtable, where she joined other female scientists and leaders to discuss strategies for breaking barriers, fostering innovation, and empowering women in STEM.
In addition, iBET scientists Daniel Simão and Sofia Silva also attended the conference.
Left to Right: Patricia Gomes-Alves, Daniel Simão and Sofia Silva.
The work presented reflects iBET’s robust analytical capabilities for in-depth bioprocess understanding and biologics’ characterization, particularly supported by its Mass Spectrometry Unit. It also underscores the institute’s ongoing commitment to advancing biopharmaceutical research.
